Colorectal cancer (CRC) constitutes a critical public health issue, compromising patients’ quality of life (QoL) and placing considerable strain on families and health services. To measure QoL and its associated factors among individuals with CRC in Qatar, and to determine the sociodemographic and clinical characteristics that shaped QoL during 2023. An analytical cross-sectional investigation was conducted between July and December 2023. Drawing from the National Center for Cancer Care and Research (NCCCR) registry, 456 CRC patients underwent screening, of whom 169 met the inclusion criteria and were enrolled. QoL was assessed using the EORTC QLQ-C30 and the CRC-specific QLQ-CR29 module. Participants were predominantly aged ≥ 45 years (80.5%), of non-Qatari nationality (79.9%), and married (88.8%). The most frequently observed comorbidities were hypertension (39.1%) and diabetes (31.4%). Adenocarcinoma represented the vast majority of histological findings (90.5%), with the bulk of diagnoses occurring at late stages (III–IV, 74.8%) and metastatic spread documented in 71.6%. The sigmoid colon emerged as the most commonly affected anatomical site (34.9%), while combined surgery and chemotherapy constituted the principal therapeutic approach (69.2%). The global QoL score was in the moderate-to-high range (70.4 ± 18.5), with fatigue (23.9 ± 26.8) and monetary hardship (28.9 ± 40.4) standing out as the most frequently reported issues. Functional QoL scores were elevated among those enjoying adequate income (+12.5 points, P < 0.01) and those with more time elapsed since diagnosis (+0.06 points/month, P < 0.05). In contrast, they were diminished among individuals with higher educational attainment (–5.0 points, P = 0.05) or a history of alcohol consumption (–11.2 points, P = 0.05). Although disease stages were typically advanced, CRC patients in Qatar recorded satisfactory QoL. Socioeconomic standing exerted a pronounced influence on outcomes, underscoring the need to integrate psychosocial and financial support services.